

Supreet Kaur, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Supreet Kaur, M.D.
Dr Supreet Kaur is an Assistant Professor in the Department of Hematology and Oncology at UT Health San Antonio MD Anderson Cancer Center. She received her medical degree from Government Medical College, Amritsar, India. She completed her residency in internal medicine and fellowship in hematology/medical oncology at St Joseph University medical Center at New York Medical College. Dr Kaur is Board certified in Internal Medicine, Hematology and Medical Oncology. Her primary clinical interests include Lymphoma and Thoracic Oncology. Her current research interests include clinical biomarkers in cancer and therapeutics. She serves as principal investigator and co-investigator in a number of clinical trials including SWOG cooperative group studies. She also serves as Associate Program Director of Hematology and Oncology Fellowship Program.
Gender
- Female
Languages Spoken
- Hindi
- Punjabi
-
Credentials
Credentials
Positions
- Assistant Professor at UT Health San Antonio
Certifications
- American Board of Internal Medicine
- American Board of Hematology
- American Board of Medical Oncology
Education
Medical School: Government Medical College, Amritsar, India
Residency: St Joseph Medical Center at New York Medical College
Fellowship: St Joseph University Medical Center
-
Locations & Contact
Locations & Contact
-
Research & Publications
-
Clinical Trials
Clinical Trials
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Supreet Kaur M.D.
S2302, PRAGMATICA – LUNG - A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small
This phase III trial compares the effect of the combination of ramucirumab and pembrolizumab versus standard of care chemotherapy for the treatment of non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Immunotherapy with…
Type of Cancer
Non-Small Cell Lung Cancer
ClinicalTrials.gov Identifier
ClinicalTrials.gov registration not required
Principal Investigator
Supreet Kaur M.D.
A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nabpaclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Nonsmall Cell Lung Cancer
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without…